(NASDAQ: INBX) Inhibrx Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 31.52%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 66.53%.
Inhibrx Biosciences's earnings in 2025 is $1,687,572,000.On average, 1 Wall Street analyst forecast INBX's earnings for 2025 to be -$150,115,124, with the lowest INBX earnings forecast at -$150,115,124, and the highest INBX earnings forecast at -$150,115,124.
In 2026, INBX is forecast to generate -$108,135,003 in earnings, with the lowest earnings forecast at -$108,135,003 and the highest earnings forecast at -$108,135,003.